FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207052357> ?p ?o ?g. }

• W4207052357 endingPage "789" @default.
• W4207052357 startingPage "778" @default.
• W4207052357 abstract "Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by the aggregation of α-synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α-synuclein autophagy and reduces its associated neurotoxicity in preclinical models.To investigate the efficacy and safety of sirolimus in patients with MSA using a futility design. We also analyzed 1-year biomarker trajectories in the trial participants.Randomized, double-blind, parallel group, placebo-controlled clinical trial at the New York University of patients with probable MSA randomly assigned (3:1) to sirolimus (2-6 mg daily) for 48 weeks or placebo. Primary endpoint was change in the Unified MSA Rating Scale (UMSARS) total score from baseline to 48 weeks. (ClinicalTrials.gov NCT03589976).The trial was stopped after a pre-planned interim analysis met futility criteria. Between August 15, 2018 and November 15, 2020, 54 participants were screened, and 47 enrolled and randomly assigned (35 sirolimus, 12 placebo). Of those randomized, 34 were included in the intention-to-treat analysis. There was no difference in change from baseline to week 48 between the sirolimus and placebo in UMSARS total score (mean difference, 2.66; 95% CI, -7.35-6.91; P = 0.648). There was no difference in UMSARS-1 and UMSARS-2 scores either. UMSARS scores changes were similar to those reported in natural history studies. Neuroimaging and blood biomarker results were similar in the sirolimus and placebo groups. Adverse events were more frequent with sirolimus. Analysis of 1-year biomarker trajectories in all participants showed that increases in blood neurofilament light chain (NfL) and reductions in whole brain volume correlated best with UMSARS progression.Sirolimus for 48 weeks was futile to slow the progression of MSA and had no effect on biomarkers compared to placebo. One-year change in blood NfL and whole brain atrophy are promising biomarkers of disease progression for future clinical trials. © 2022 International Parkinson and Movement Disorder Society." @default.
• W4207052357 created "2022-01-26" @default.
• W4207052357 creator A5004353870 @default.
• W4207052357 creator A5006920486 @default.
• W4207052357 creator A5010687217 @default.
• W4207052357 creator A5025382745 @default.
• W4207052357 creator A5026667129 @default.
• W4207052357 creator A5030145540 @default.
• W4207052357 creator A5035774671 @default.
• W4207052357 creator A5041731567 @default.
• W4207052357 creator A5050948560 @default.
• W4207052357 creator A5051279500 @default.
• W4207052357 creator A5065113173 @default.
• W4207052357 creator A5068887042 @default.
• W4207052357 creator A5079876124 @default.
• W4207052357 creator A5084155345 @default.
• W4207052357 date "2022-01-18" @default.
• W4207052357 modified "2023-10-18" @default.
• W4207052357 title "<scp>mTOR</scp> Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis" @default.
• W4207052357 cites W1717443879 @default.
• W4207052357 cites W1979783084 @default.
• W4207052357 cites W2003738638 @default.
• W4207052357 cites W2011134915 @default.
• W4207052357 cites W2044841974 @default.
• W4207052357 cites W2068288454 @default.
• W4207052357 cites W2079556917 @default.
• W4207052357 cites W2081096442 @default.
• W4207052357 cites W2085482175 @default.
• W4207052357 cites W2111567059 @default.
• W4207052357 cites W2113803769 @default.
• W4207052357 cites W2116622644 @default.
• W4207052357 cites W2117626437 @default.
• W4207052357 cites W2125766898 @default.
• W4207052357 cites W2141041456 @default.
• W4207052357 cites W2141370620 @default.
• W4207052357 cites W2155299862 @default.
• W4207052357 cites W2163628807 @default.
• W4207052357 cites W2166522195 @default.
• W4207052357 cites W2166557928 @default.
• W4207052357 cites W2257271597 @default.
• W4207052357 cites W2411905225 @default.
• W4207052357 cites W2504366495 @default.
• W4207052357 cites W2517054293 @default.
• W4207052357 cites W2610398856 @default.
• W4207052357 cites W2614974832 @default.
• W4207052357 cites W2621449524 @default.
• W4207052357 cites W2807994366 @default.
• W4207052357 cites W2887708784 @default.
• W4207052357 cites W2920820971 @default.
• W4207052357 cites W2946930832 @default.
• W4207052357 cites W2954510583 @default.
• W4207052357 cites W2965362584 @default.
• W4207052357 cites W2967878847 @default.
• W4207052357 cites W3129082778 @default.
• W4207052357 cites W3162121356 @default.
• W4207052357 doi "https://doi.org/10.1002/mds.28923" @default.
• W4207052357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35040506" @default.
• W4207052357 hasPublicationYear "2022" @default.
• W4207052357 type Work @default.
• W4207052357 citedByCount "12" @default.
• W4207052357 countsByYear W42070523572022 @default.
• W4207052357 countsByYear W42070523572023 @default.
• W4207052357 crossrefType "journal-article" @default.
• W4207052357 hasAuthorship W4207052357A5004353870 @default.
• W4207052357 hasAuthorship W4207052357A5006920486 @default.
• W4207052357 hasAuthorship W4207052357A5010687217 @default.
• W4207052357 hasAuthorship W4207052357A5025382745 @default.
• W4207052357 hasAuthorship W4207052357A5026667129 @default.
• W4207052357 hasAuthorship W4207052357A5030145540 @default.
• W4207052357 hasAuthorship W4207052357A5035774671 @default.
• W4207052357 hasAuthorship W4207052357A5041731567 @default.
• W4207052357 hasAuthorship W4207052357A5050948560 @default.
• W4207052357 hasAuthorship W4207052357A5051279500 @default.
• W4207052357 hasAuthorship W4207052357A5065113173 @default.
• W4207052357 hasAuthorship W4207052357A5068887042 @default.
• W4207052357 hasAuthorship W4207052357A5079876124 @default.
• W4207052357 hasAuthorship W4207052357A5084155345 @default.
• W4207052357 hasBestOaLocation W42070523572 @default.
• W4207052357 hasConcept C126322002 @default.
• W4207052357 hasConcept C142724271 @default.
• W4207052357 hasConcept C143998085 @default.
• W4207052357 hasConcept C168563851 @default.
• W4207052357 hasConcept C197934379 @default.
• W4207052357 hasConcept C203092338 @default.
• W4207052357 hasConcept C204787440 @default.
• W4207052357 hasConcept C27081682 @default.
• W4207052357 hasConcept C2777921159 @default.
• W4207052357 hasConcept C2781197716 @default.
• W4207052357 hasConcept C55493867 @default.
• W4207052357 hasConcept C61943457 @default.
• W4207052357 hasConcept C71924100 @default.
• W4207052357 hasConcept C86803240 @default.
• W4207052357 hasConceptScore W4207052357C126322002 @default.
• W4207052357 hasConceptScore W4207052357C142724271 @default.
• W4207052357 hasConceptScore W4207052357C143998085 @default.
• W4207052357 hasConceptScore W4207052357C168563851 @default.
• W4207052357 hasConceptScore W4207052357C197934379 @default.
• W4207052357 hasConceptScore W4207052357C203092338 @default.

• next